Barclays reissued their overweight rating on shares of Dr. Martens (LON:DOCS – Get Rating) in a research report released on Monday morning, MarketBeat Ratings reports. The brokerage currently has a GBX 175 ($2.18) price target on the stock. A number of other analysts have also recently weighed in on DOCS. Numis Securities reiterated an add […]